OptiCancer is an electronic report made in Germany, after analyzing the biopsy of a cancer patient that considers individual differences in people’s genes, environments,and family history to define individual patterns of disease. It utilizes the newest and well established German capabilities and expertise which are available in the Frankfurt Innovation Center for Biotechnology “FIZ”. OptiCancer is an innovative project powered by CEDEM AG. In January 2017, CEDEM AG signed an agreement with FIZ to represent them in the MENA region. This is an attempt to move the most reputable German technologies “Precision Medicine” which are combined with the humanization of business to serve the communities of middle and low income by offering economical prices.